Correction to: Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
Qual Life Res
.
2021 Feb;30(2):465-466.
doi: 10.1007/s11136-020-02720-1.
Authors
Janet H Ford
1
,
Virginia L Stauffer
2
,
Peter McAllister
3
,
Sreelatha Akkala
4
,
Matthew Sexson
2
,
David W Ayer
2
,
Shufang Wang
2
Affiliations
1
Eli Lilly and Company, 893 S. Delaware Street, Indianapolis, IN, 46225, USA.
[email protected]
.
2
Eli Lilly and Company, 893 S. Delaware Street, Indianapolis, IN, 46225, USA.
3
New England Institute for Neurology and Headache, Stamford, USA.
4
Eli Lilly Services India Pvt Ltd, Bengaluru, India.
PMID:
33340061
PMCID:
PMC8025266
DOI:
10.1007/s11136-020-02720-1
No abstract available
Publication types
Published Erratum